Skip to main navigation
Tenaya Therapeutics
  • Careers at Tenaya
  • Contact Us
  • Leadership
  • Our Science
    • Platforms
    • Capabilities
    • Collaborations
    • Publications & Presentations
  • Our Programs
    • Pipeline
    • Programs
  • Patients
    • Elevating Patient Voices
    • Advocacy at Tenaya
    • Clinical Studies
    • Gene Therapy for Cardiomyopathies
    • Advocacy Partners
  • Investors
    • News & Events
      • Press Releases
      • Events & Presentations
    • Corporate Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
    • Financial Information
      • SEC Filings
      • Quarterly Results
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • IR Resources
      • Investor FAQs
      • Contact IR
      • Email Alerts
  • HCP Resource Center
    • Genetic Medicine Primer
      • About Gene Therapy
    • TN-201 for MYBPC3– associated HCM
      • Hypertrophic Cardiomyopathy and Genetics
      • How TN-201 Works
      • MyPEAK-1 Phase 1b/2 Clinical Trial
      • Tenaya’s Non-interventional Studies for MYBPC3 HCM
      • Webinars
      • FAQ’s
    • TN-401 for PKP2– associated ARVC
      • ARVC and Genetics
      • How TN-401 works
      • RIDGE-1 Phase 1b Clinical Trial
      • Tenaya’s Non-interventional Study for PKP2-Associated ARVC
      • FAQ’s

Investor Portal

Endpoints: Tenaya Therapeutics completes buildout of Bay Area genetic medicine manufacturing site

Jun 23, 2022
PDF Version
Tyler Patchen of Endpoints reports on Tenaya’s new manufacturing facility, which launched operations in June of 2022.

Read More

RSS Feeds
Email Alerts
Contact IR
Print

Privacy Policy | Cookie Policy | Terms of Use | Community Guidelines
© 2026 Tenaya Therapeutics. All rights reserved.